Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Biotechnology
British drugmaker AstraZeneca has gained European approval for Imfinzi (durvalumab) in combination with chemotherapy as a treatment for resectable muscle-invasive bladder cancer. The green light makes Imfinzi the first immunotherapy approved in the EU for perioperative use in this aggressive cancer type. 4 July 2025
Related News
Insights
Company Spotlight
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies.
Latest News & Features of interest to Bristol Myers Squibb
Pharmaceutical
Mental health company atai Life Sciences was trading more than 31% higher during Tuesday morning’s trading in New York. 1 July 2025
Biotechnology
Marking a new step forward in its international growth, Spanish privately-held pharma company Esteve has entered into an agreement with Sanofi to acquire French pharma major Sanofi’s Caprelsa (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children above five years of age to treat aggressive and symptomatic medullary thyroid cancer. 1 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD)—including certain formulations of amphetamine and methylphenidate—to warn of the risk of weight loss and other adverse reactions in patients younger than six years. 1 July 2025
Biotechnology
Denmark-based Vesper Bio, a biotech developing an oral therapy for frontotemporal dementia, has announced the appointment of Jacob Falck Hansen as chief executive. 1 July 2025
Biotechnology
Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical collaboration in multiple solid tumor settings. 1 July 2025
Pharmaceutical
Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its primary endpoint. However, the company is now pointing to encouraging signs in a subset of patients, which it says could guide future development of its candidate, XPro (pegipanermin). 1 July 2025
Pharmaceutical
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025
Biotechnology
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
Biotechnology
US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. 30 June 2025
Latest In Brief for Bristol Myers Squibb
Pharmaceutical
Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with prednisone or prednisolone for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) and homologous recombination repair (HRR) gene alterations. 3 July 2025
Latest Relevant Ones To Watch News
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic. 6 July 2025
30 June 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze